Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Hodgkin Disease 2Hemoglobinuria, Paroxysmal 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Leukemia 1Histiocytosis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Antibodies × Clear all
NCT02458638 2021-06-04

A Study of Atezolizumab in Advanced Solid Tumors

Hoffmann-La Roche

Phase 2 Completed
474 enrolled 14 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡